Celgene Corp (CELG)

CELG (NASDAQ:Drugs) EQUITY
$114.75
pos +1.28
+1.13%
Today's Range: 113.03 - 114.77 | CELG Avg Daily Volume: 5,446,400
Last Update: 04/20/15 - 4:14 PM EDT
Volume: 4,487,201
YTD Performance: 2.58%
Open: $114.40
Previous Close: $113.47
52 Week Range: $68.38 - $129.06
Oustanding Shares: 800,590,656
Market Cap: 90,843,021,736
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 13 14 14 14
Moderate Buy 1 1 1 1
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.50 1.47 1.47 1.47
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 47.48
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
47.48 47.40 27.68
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-6.90% 62.18% 190.14%
GROWTH 12 Mo 3 Yr CAGR
Revenue 18.10 0.58 0.16
Net Income 37.90 0.52 0.15
EPS 42.00 0.72 0.20
Earnings for CELG:
EBITDA 2.94B
Revenue 7.67B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.93 $1.05 $4.42 $6.19
Number of Analysts 4 4 4 4
High Estimate $1.01 $1.12 $4.73 $7.21
Low Estimate $0.87 $0.98 $4.23 $5.45
Prior Year $0.73 $0.80 $3.36 $4.42
Growth Rate (Year over Year) 27.05% 31.25% 31.62% 39.97%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Apr 8, 2015 | 3:46 PM EDT

Even the second-tier biotechs are taking off.

By

Jim Cramer

 | Apr 7, 2015 | 4:50 AM EDT

The weak dollar was the breeze that pushed the market higher.

By

Carolyn Boroden

 | Mar 30, 2015 | 7:37 AM EDT

Three stocks were ripe for buying after the pullback.

By

Jim Cramer

 | Mar 30, 2015 | 5:39 AM EDT

An answer to those asking me what's worth buying.

By

Jim Cramer

 | Mar 27, 2015 | 5:21 AM EDT

If there is no catalyst, I'd join those who sell on a bounce.

By

Jim Cramer

 | Mar 26, 2015 | 5:47 PM EDT

It takes a village of positive reports to sustain market.

By

Robert Lang

 | Mar 23, 2015 | 9:31 AM EDT

Where are Celgene, Isis and CVS heading?

By

Jim Cramer

 | Mar 23, 2015 | 6:00 AM EDT

Here are healthcare stocks of all shares and sizes with strong charts.

By

Jim Cramer

 | Mar 21, 2015 | 2:30 PM EDT

Own them, or take something off the table?

By

Jim Cramer

 | Mar 20, 2015 | 10:53 AM EDT

I really like the stocks. But I also like making money on stocks.

Kimberly-Clark had some good gains in adult care, Huggies wipes and tissue in the first qu...
Monday's market action was impressive and may very well be the first leg of another assaul...
The blame for the eventual fallout of central banker excess will go to the 'other' politic...
Regarding central banks' inflating asset prices, the wider point is that they are undemocr...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.